Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Veracyte, Inc.

R&D Spending: Alnylam vs. Veracyte - A Decade of Innovation

__timestampAlnylam Pharmaceuticals, Inc.Veracyte, Inc.
Wednesday, January 1, 20141902490009804000
Thursday, January 1, 201527649500012796000
Friday, January 1, 201638239200015324000
Sunday, January 1, 201739063500013881000
Monday, January 1, 201850542000014820000
Tuesday, January 1, 201965511400014851000
Wednesday, January 1, 202065481900017204000
Friday, January 1, 202179215600029843000
Saturday, January 1, 202288301500040603000
Sunday, January 1, 2023100441500057305000
Monday, January 1, 20241126232000
Loading chart...

Unleashing the power of data

A Decade of Innovation: R&D Spending Trends

In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Alnylam Pharmaceuticals, Inc. and Veracyte, Inc. have demonstrated contrasting approaches to R&D investment.

Alnylam Pharmaceuticals, Inc.

Since 2014, Alnylam has consistently increased its R&D budget, culminating in a 428% rise by 2023. This substantial growth underscores Alnylam's dedication to pioneering RNA interference therapeutics, positioning it as a leader in the biotech sector.

Veracyte, Inc.

Conversely, Veracyte's R&D spending has grown at a more modest pace, with a 484% increase over the same period. This steady investment reflects Veracyte's strategic focus on advancing genomic diagnostics, ensuring precision medicine remains at the forefront of their mission.

These divergent strategies highlight the varied paths companies take in the pursuit of scientific breakthroughs.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025